A5029294647- Chronic Obstructive Pulmonary Disease (COPD) Research
- Asthma and respiratory diseases
- Bacterial Infections and Vaccines
- Inhalation and Respiratory Drug Delivery
- Vaccine Coverage and Hesitancy
- Respiratory and Cough-Related Research
- Pneumonia and Respiratory Infections
- Health Systems, Economic Evaluations, Quality of Life
- HIV/AIDS Research and Interventions
- Systemic Lupus Erythematosus Research
- Respiratory Support and Mechanisms
- HIV/AIDS drug development and treatment
- Herpesvirus Infections and Treatments
- Peripheral Neuropathies and Disorders
- Systemic Sclerosis and Related Diseases
- Infective Endocarditis Diagnosis and Management
- Pharmaceutical studies and practices
- Influenza Virus Research Studies
- Poxvirus research and outbreaks
- Autoimmune Bullous Skin Diseases
- Cardiac Arrhythmias and Treatments
- Cytomegalovirus and herpesvirus research
- Delphi Technique in Research
- Public Health and Social Inequalities
- Virology and Viral Diseases
GlaxoSmithKline (Spain)
2014-2024
Protection against vaccine-preventable diseases is especially relevant in older adults due to age-related decline immunity (immunosenescence). However, adult vaccination remains a challenge with overall low coverage rates, which has an impact on both the patients who have these and health care system terms of resource use costs derived. This study aimed estimate direct economic herpes zoster, pneumococcal disease, influenza pertussis Spanish 45 years older.Data from 2015 were extracted two...
Current antiretroviral therapies (ARTs) have improved outcomes for people living with HIV. However, the requirement to adhere lifelong daily oral dosing may be challenging some HIV, leading suboptimal adherence and therefore reduced treatment effectiveness. Treatment long-acting (LA) ART improve health-related quality of life. The objective this study was evaluate cost-effectiveness cabotegravir + rilpivirine (CAB+RPV) LA administered every 2 months (Q2M) compared current as single-tablet...
Immunization is the most effective strategy for prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MenB); however, parents need to weigh risk–benefit and financial impact immunizing their children against MenB in absence a national immunization program (NIP). This study aimed explore societal preferences (of pediatricians) regarding attributes vaccine Spain. A discrete choice experiment (DCE) based on cross-sectional surveys was carried out determine...
A head-to-head study demonstrated the superiority of once-daily umeclidinium bromide/vilanterol (UMEC/VI) 62.5/25 mcg on trough forced expiratory volume in 1 s (FEV1) versus tiotropium/olodaterol (TIO/OLO) 5/5 symptomatic patients with chronic obstructive pulmonary disease (COPD). This analysis evaluated cost effectiveness UMEC/VI TIO/OLO from a Spanish National Healthcare System perspective, using data this and literature. was conducted perspective 3-year horizon as base case. progression...
Given between-country differences in healthcare systems, treatment costs, and disease management guidelines, country-specific cost-effectiveness analyses are important. This study evaluated the of once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus FF/VI UMEC/VI among patients with symptomatic chronic obstructive pulmonary (COPD) at risk exacerbations from a Spanish system perspective.Baseline data effects IMPACT trial were populated into validated GALAXY COPD...
The recombinant zoster vaccine (RZV) is included in the Spanish National Immunisation Programme for adults 65 years of age (years), with a potential progressive catch-up program 66–80 years, starting 80 years. However, risk herpes (HZ) increases significantly from 50 We estimated public health impact (PHI) vaccinating ≥50 Spain versus no vaccination, using Markov model adapted to setting. simulated hypothetical cohort over lifetime, inputs publications, databases, or publications other...
Despite its impact on a patient's life, there is paucity of evidence the humanistic burden invasive meningococcal disease (IMD) due to serogroup B (MenB) in Spain. This study estimates total quality-adjusted life-year (QALY) loss MenB-IMD Spain from societal perspective.
Broad benefits of vaccination programs are well acknowledged but difficult to measure, especially when considering all vaccines included in a National Immunization Program (NIP). The aim was conduct cost-benefit analysis the entire NIP Spain, and an expanded including four potential additional programs. A performed Excel assess economic health (€) vaccinating single cohort newborns over lifetime horizon compared no vaccination, from societal perspective: firstly, according 2020 Spain...
Objectives: The Salford Lung Study in Chronic Obstructive Pulmonary Disease (SLS COPD) is a 12-month, open-label randomized clinical trial comparing effectiveness and safety of initiating once-daily fluticasone furoate/vilanterol (FF/VI) 92/22 mcg with continuing usual care (UC) patients COPD followed primary the UK. objective this analysis to estimate economic impact these results when applied Spain. Materials methods: An Excel-based cost–consequence model one-year time horizon was...
Invasive meningococcal disease (IMD) is a severe infectious disease, mainly affecting children under 5 years, associated with long-term physical, neurological and psychological sequelae. In Spain, most IMD cases are caused by serogroup B (MenB). This study estimates its economic burden from societal perspective in Spain.A previously published bottom-up, model-based incidence costing approach Scholz et al. (2019) to estimate the of MenB Germany was adapted Spanish setting. Diagnosis...
The Salford Lung Study in asthma (SLS asthma) is a 12-month, open-label randomised clinical trial comparing effectiveness of initiating once-daily inhaled combination fluticasone furoate/vilanterol (FF/VI) 184/22 mcg or 92/22 mcg, with continuing optimized usual care (UC) corticosteroids (ICS) alone, long-acting β2-agonist (ICS/LABA), asthmatic patients followed primary the UK. objective analysis to estimate economic impact these results when applied Spain.A 1-year cost-consequence model was...
Purpose: To determine the clinical and economic impact of inhaled corticosteroid (ICS) withdrawal in Spanish patients with COPD receiving triple therapy (TT) ICS, long-acting β 2 -agonist (LABA), muscarinic antagonist (LAMA). Patients Methods: This was an observational, retrospective study BIG-PAC database medical records. aged ≥ 40 years TT from 2016 to 2018 were followed for 1 year. Two cohorts identified: continuing (ICS+LABA+LAMA), ICS withdrawn (LABA+LAMA). Variables included...
<b>Introduction:</b> The IMPACT study (NCT02164513) demonstrated the clinical benefit of single-inhaler triple therapy (fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI)) versus dual with FF/VI and UMEC/VI in patients moderate/severe COPD. <b>Objective:</b> To evaluate differences healthcare resource use (HRU) associated costs between FF/UMEC/VI, FF/VI, UMEC/VI, among COPD using data from trial, a Spanish National Healthcare System (NHS) perspective. <b>Methods:</b> This is...
<b>Introduction:</b> COPD is an important public health concern in Spain, associated with high healthcare resource utilization (HRU) and cost burden. Several studies show that using triple therapy (ICS+LAMA+LABA) can reduce hospitalization rates compared dual or monotherapy. <b>Objective:</b> To evaluate the impact of once-daily single inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 92/55/22µg on HRU costs twice-daily budesonide/formoterol (BUD/FOR) 320/9µg among patients...